key: cord-0811518-ubmz5exm authors: Naranbhai, V.; Garcia-Beltran, W. F.; Mairena, C. B.; Thierauf, J. C.; Chang, C. C.; Kirkpatrick, G.; Onozato, M. L.; Cheng, J.; St. Denis, K.; Lam, E. C.; Kaseke, C.; Tano-Menka, R.; Yang, D.; Pavlovic, M.; Yang, W.; Kui, A.; Miller, T. E.; Astudillo, M. G.; Cahill, J. E.; Dighe, A.; Gregory, D. J.; Poznansky, M. C.; Gaiha, G.; Balazs, A. B.; Iafrate, A. J. title: Immunogenicity of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines date: 2021-07-22 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2021.07.18.21260732 sha: a64197bfd6591324e82f8e9bf4b015f69028d7a2 doc_id: 811518 cord_uid: ubmz5exm Background: Understanding variation in immunogenicity may help rationalize use of existing SARS-CoV-2 vaccines. Methods: We compared immune responses in ambulatory adults vaccinated with mRNA-1273 , BNT-162b2 or Ad26.COV2.S in Massachusetts, USA between February and May 2021. Control groups were pre-pandemic controls (n=1220) and individuals without (n=112) or with prior SARS-CoV-2 infection (n=130) sampled in mid-2020. We measured total anti-spike IgG/M/A antibodies (Roche Elecsys Anti-SARS-COV-2 S assay), anti-receptor-binding-domain (RBD) antibodies; neutralization of SARS-CoV-2 pseudovirus; and T-cell responses. Findings In individuals with prior infection, all vaccines were associated with higher antibody concentrations and neutralization than those in convalescent individuals, even after a single dose. In individuals without prior infection, a single dose of either mRNA vaccine yielded comparable concentrations and neutralization to convalescent unvaccinated individuals, and Ad26.COV2.S yielded lower antibody concentrations and neutralization titers. The second dose of either mRNA vaccine boosted responses. At a median of 24 days after vaccination, two of 21 (9.5%) Ad26.COV2.S recipients had a neutralization titer higher than pre-pandemic controls; repeat sampling at a median 66 days after vaccination found most (11/15 (73%) remained negative. Antibody concentrations and neutralization titers increased similarly after the first dose of either vaccine, and even further in recipients of a second dose of vaccine. T-cell responses were higher in mRNA1273 and BNT162b2 than Ad26.COV2.S recipients. Interpretation SARS-CoV-2 vaccines vary significantly in immunogenicity in individuals without prior infection. If confirmed in effectiveness studies, public health policy may need to be tailored to each vaccine, or even individual responses. Prophylactic vaccines against SARS-CoV-2 are being deployed globally to combat the COVID-19 pandemic. There are few data regarding the comparative immunogenicity of these vaccines, except for indirect inferences from publicly available trial data from manufacturers [1] [2] [3] [4] [5] [6] . Immunogenicity measures of different vaccines may be important to quantitate as we seek to understand variation in vaccine effectiveness between individuals. We characterized the immunogenicity of mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech) and Ad26.COV2.S (Johnson & Johnson (Janssen)) in ambulatory adults enrolled in an ongoing community study in Chelsea, Massachusetts and a vaccine biobanking effort in Boston, Massachusetts. In total we include data from 215 participants who had received one (n = 99) or two doses (n = 116) of vaccine ≥ 7 days prior, 130 unvaccinated participants with asymptomatic or symptomatic prior infection confirmed by positive anti-nucleocapsid antibody, 112 uninfected (anti-nucleocapsid antibody negative), and 1,220 historical controls sampled before the pandemic 7 . The median age of vaccinated participants was 39 years (IQR 31-55 years) and 120/215 (56%) were female (Supplementary Table 1 ). We compared immune responses according to prior infection, and vaccination type and dose and adjusted for age, sex and duration after vaccination in all analyses. We assessed total IgG/M/A binding antibody levels against the SARS-CoV-2 spike protein (Roche Elecsys Anti-SARS-CoV-2 S), and found substantial variation in antibody concentrations depending on prior infection, vaccine type and vaccine dose (Figure 1A , summarized in a multivariate regression model in Supplementary Table 2 ). Among participants without prior infection, antibody concentrations after a single dose of mRNA-1273 or BNT162b2 were comparable or slightly lower than convalescent individuals (geometric mean concentration in U/mL (GMC) 222 vs. 189, adjusted p=0.4 for mRNA-1273 and 71 vs. 189, adjusted p=0.01 for BNT162b2). In contrast, recipients of Ad26.COV2.S with no prior infection had significantly lower antibody concentrations than convalescent unvaccinated individuals (GMC 6.9 vs 189, adjusted p <0.001). Although participants with no prior infection who received a single dose of either of the three vaccines were sampled at a comparable duration after vaccination (a median of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.18.21260732 doi: medRxiv preprint 22-24 days), a single dose of mRNA-1273 or BNT162b2 generated higher titers than Ad26.COV2.S (adjusted p < 0.001 for both comparisons, Supplementary Table 3) . At a median of 24 days post-vaccination, seven of twenty-two (17.3%) Ad26.COV2.S recipients had undetectable antibody levels. We confirmed that all 22 Ad26.COV2.S recipients had no major medical comorbidity and were not on immunosuppressive medications in the prior six months. Receipt of both doses of mRNA-1273 or BNT162b2 were associated with substantially higher antibody concentrations than convalescent individuals (GMC 6486 for mRNA-1273 and GMC 2455 for BNT162b2 vs. 189, adjusted p<0.001 for both comparisons). Individuals with prior infection who were vaccinated had ~2 log 10 IU/ml higher antibody concentrations than convalescent individuals regardless of vaccine type, even after a single dose and there was a nonsignificant pattern towards lower concentrations in Ad26.COV2.S recipients. Using an independent validated total IgG/M/A or IgG ELISA, measurement of receptor binding domain (RBD) binding antibodies confirmed the differences above; and IgM and IgA responses were low ( Figure S1 ). Further measurement of IgG against RBD-multimers also confirmed these findings ( Figure S2 ). IgG responses against equivalent RBD-multimers of less pathogenic, common coronaviruses OCU43 and HKU1 were comparable between groups supporting the specificity of this finding ( Figure S3 ). Correlative analysis of the SARS-CoV-2 vaccine trials demonstrate that neutralizing antibody titer is associated with the degree of protection observed 89 . In animal models, experimental transfer of antibodies protects from infection 10, 11 and in human randomized controlled-trials, prophylactic administration of neutralizing antibodies reduces incidence of clinical COVID-19 12, 13 . We assessed neutralization of pseudoviruses representing the original Wuhan isolate of Table 4 ) and 78% and 86% neutralized virus. Titers were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.18.21260732 doi: medRxiv preprint higher after both doses of mRNA vaccine (GMT 715 for mRNA1273 and 927 for BNT162b2, adjusted p<0.001 for both), and serum from all mRNA vaccinees neutralized wild-type SARS-CoV-2 pseudovirus. In contrast, only two of 21 (9.5%) Ad26.COV2.S recipients had a neutralization titer >1:20. Among individuals with prior infection, receipt of one or two doses of either of the three vaccines, generated high neutralization titers. To evaluate the described increase in anti-SARS-CoV-2 antibodies at later timepoints in Constraining analysis to the period prior to the second mRNA vaccine effect (ie. the first four weeks for BNT162b2 and five weeks for mRNA1273), titers increased for all three vaccines, and the rate of increase was not statistically dissimilar between vaccines (interaction p=0.85). In this cohort, 80% of convalescent individuals have a pNT50 of greater than 45.6, corresponding with published estimates of the threshold for ~50% protection 8 . Using this threshold, most recipients of mRNA-1273 and BNT162b2 achieved predicted protective neutralization titers rapidly, before receipt of the second dose of vaccination, and these appear to be sustained for several months ( Figure 2D) . In contrast, most Ad26.COV2.S recipients did not neutralize virus even after 6 weeks. Since previously published studies of Ad26.COV2.S recipients that have described a more robust increase in neutralization utilized the Victoria strain of SARS CoV-2 2,3 , a strain that has been noted to be more easily neutralized 14 , we introduced the Victoria strain-associated S247R mutation into the SARS CoV-2 Wuhan isolate used in this study. Sera from vaccine recipients demonstrated higher neutralization titers against this S247R-containing variant than the original Wuhan strain regardless of vaccine administered (Figure S4 ). Therefore differences All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.18.21260732 doi: medRxiv preprint in the described neutralization seen in this study vs. the Ad26.COV2.S trials 2,3 may be partially accounted for by use of the S247R viral variant in prior studies. To explore differences in cellular immune response to vaccination, we assessed T-cell responses to SARS-CoV-2 spike peptides (wild-type strain) by IFN-γ ELISpot in a subset of uninfected vaccinees who completed their vaccination schedule (Figure 3) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.18.21260732 doi: medRxiv preprint Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. The New England journal of medicine Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Article Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Correlates of protection against SARS-CoV-2 in rhesus macaques Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV TM (casirivimab with imdevimab) | Regeneron Pharmaceuticals Inc. Accessed Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC  We thank Andrea Nixon and the MGH Core laboratory for assistance in performing assays. We wish to thank Michael Farzan, PhD for providing ACE2-expressing 293T cells and Aaron Schmidt for providing proteins for development of ELISA assays and Atul Bhan, MD and Mandakolathur Murali, MD for useful and insightful discussion. The RBD ELISA assay was